SuperworthIntellia Therapeutics market cap NTLA
Share price times shares outstanding: what the whole company sells for, since 2016.
- Today, Oct 23, 2026
- $1.6B
- Highest close in our data
- $13B
- Sep 2021
Intellia Therapeutics is worth $1.6B at the close on Oct 23, 2026, at $11.21 a share.
That is down 43% over the last year and down 84% over five years.
Its highest close in our data was $13B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.6B | $1.1B | $2.5B | +44% |
| 2025 | $1.1B | $686.3M | $2.7B | −10% |
| 2024 | $1.2B | $1.2B | $3.1B | −55% |
| 2023 | $2.7B | $2B | $4B | −1% |
| 2022 | $2.7B | $2.7B | $7.9B | −69% |
| 2021 | $8.8B | $3.5B | $13B | +174% |
| 2020 | $3.2B | $578.8M | $3.7B | +328% |
| 2019 | $751.8M | $530.6M | $855.8M | +34% |
| 2018 | $563.1M | $494.5M | $1.4B | −19% |
| 2017 | $693.6M | $440.9M | $1.1B | +47% |
| 2016 | $471.9M | $462.9M | $975.5M | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest Intellia Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| NTLAIntellia Therapeutics | $1.6B |
| CDNACareDx | $3.6B |
| VCYTVeracyte | $3.9B |
| BLLNBillionToOne | $5.1B |
| NRCNRC Health | $485.1M |
| LNTHLantheus | $6.5B |
| CAICaris Life Sciences | $9B |
| BIOBio-Rad Laboratories | $9.9B |
| Peer median | $5.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Intellia Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.